Rx Safety Bill Would Require Renegotiation Of User Fees, FDA Tells Senate
Executive Summary
An expansion of FDA's drug safety authorities as envisioned by legislation from Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., would require a renegotiation of user fees with industry, Commissioner Andrew von Eschenbach said
You may also be interested in...
PDUFA Draft Bill Adds $70 Mil. For Rx Safety To User Fee Totals; Mark-Up Looms
A draft of the bill to reauthorize FDA's user fee program would add $70 million to the total fee negotiated by the agency and industry in order to pay for additional Rx safety oversight
PDUFA Draft Bill Adds $70 Mil. For Rx Safety To User Fee Totals; Mark-Up Looms
A draft of the bill to reauthorize FDA's user fee program would add $70 million to the total fee negotiated by the agency and industry in order to pay for additional Rx safety oversight
Will Zelnorm Tip The Scales To Increased Drug Safety Oversight Thru PDUFA?
Novartis' suspension of marketing of Zelnorm could add momentum to efforts to attach drug safety reform language to the Prescription Drug User Fee Act reauthorization legislation